Skip to main content
Top
Published in: Osteoporosis International 3/2015

01-03-2015 | Original Article

Bone health management in men undergoing ADT: examining enablers and barriers to care

Authors: A. N. Damji, K. Bies, S. M. H. Alibhai, J. M. Jones

Published in: Osteoporosis International | Issue 3/2015

Login to get access

Abstract

Summary

The study determined prostate cancer specialists’ knowledge and concordance to guidelines regarding the diagnosis, management, and prevention of androgen deprivation therapy-induced osteoporosis. Despite high knowledge regarding bone health, most respondents did not routinely measure bone mineral density or use fracture risk assessment tools, suggesting a significant gap in the screening/monitoring of bone health.

Introduction

The purpose of this study was to determine prostate cancer specialists’ knowledge, practices, self-perceived competencies and barriers to providing guideline-concordant care in the diagnosis, prevention, and management of androgen deprivation therapy (ADT)-induced osteoporosis (OP).

Methods

A number of 73 Canadian radiation oncologists and 83 urologists completed questionnaires assessing (i) knowledge regarding OP and consensus guidelines for bone health management in men receiving ADT, (ii) self-assessed competencies regarding bone health management, (iii) current practices regarding OP prevention and management, and (iv) self-perceived barriers to providing guideline-concordant care.

Results

The majority of respondents were able to correctly identify the guideline-concordant frequency of repeat dual-energy X-Ray absorptiometry (DXA) scans (76.3 %), vitamin D (70.3 %), and calcium (53.2 %) intake and that bisphosphonates/denosumab should always be considered for patients with a history of one low-trauma fracture (57.6 %). Just under 1/3 (32.5 %) reported routinely measuring bone mineral density (BMD) prior to starting ADT and routinely measuring BMD 1–2 years following the initiation of ADT (36.6 %). Only 4.6 % of respondents routinely used a validated fracture risk assessment tool. Lowest self-assessed competency levels were reported in providing self-management education to patients to foster the uptake of healthy bone behaviors (HBBs) and managing patients who present with or develop osteopenia and OP. The most significant barriers to providing OP prevention and management were lack of time and lack of supporting structures.

Conclusions

Despite high knowledge about appropriate bone health care among prostate cancer specialists, there remain significant gaps in screening and monitoring of bone health, suggesting the need to develop innovative strategies to overcome barriers to implementation.
Literature
1.
go back to reference Shahinian VB, Kuo YF, Freeman JL, Orihuela E, Goodwin JS (2005) Increasing use of gonadotropin-releasing hormone agonists for the treatment of localized prostate carcinoma. Cancer 103(8):1615–24, Epub 2005/03/03CrossRefPubMed Shahinian VB, Kuo YF, Freeman JL, Orihuela E, Goodwin JS (2005) Increasing use of gonadotropin-releasing hormone agonists for the treatment of localized prostate carcinoma. Cancer 103(8):1615–24, Epub 2005/03/03CrossRefPubMed
2.
go back to reference Cooperberg M, Grossfeld G, Lubeck D, Carroll P (2003) National practice patterns and time trends in androgen ablation for localized prostate cancer. J Natl Cancer Inst 95(13):981–9CrossRefPubMedCentralPubMed Cooperberg M, Grossfeld G, Lubeck D, Carroll P (2003) National practice patterns and time trends in androgen ablation for localized prostate cancer. J Natl Cancer Inst 95(13):981–9CrossRefPubMedCentralPubMed
3.
go back to reference Kim HS, Freedland SJ (2010) Androgen deprivation therapy in prostate cancer: anticipated side-effects and their management. Curr Opin Support Palliat Care 4(3):147–52, Epub 2010/07/02CrossRefPubMed Kim HS, Freedland SJ (2010) Androgen deprivation therapy in prostate cancer: anticipated side-effects and their management. Curr Opin Support Palliat Care 4(3):147–52, Epub 2010/07/02CrossRefPubMed
4.
go back to reference Greenspan S, Coates P, Sereika S, Nelson J, Trump D, Resnick N (2005) Bone loss after initiation of androgen deprivation therapy in patients with prostate cancer. J Clin Endocrinol Metab 90(12):6410–7, Epub 2005/09/29CrossRefPubMed Greenspan S, Coates P, Sereika S, Nelson J, Trump D, Resnick N (2005) Bone loss after initiation of androgen deprivation therapy in patients with prostate cancer. J Clin Endocrinol Metab 90(12):6410–7, Epub 2005/09/29CrossRefPubMed
5.
go back to reference Alibhai SM, Gogov S, Allibhai Z (2006) Long-term side effects of androgen deprivation therapy in men with non-metastatic prostate cancer: a systematic literature review. Crit Rev Oncol/Hematol 60(3):201–15, Epub 2006/07/25CrossRef Alibhai SM, Gogov S, Allibhai Z (2006) Long-term side effects of androgen deprivation therapy in men with non-metastatic prostate cancer: a systematic literature review. Crit Rev Oncol/Hematol 60(3):201–15, Epub 2006/07/25CrossRef
6.
go back to reference Shahinian V, Kuo Y, Freeman J, Goodwin J (2005) Risk of fracture after androgen deprivation for prostate cancer. N Engl J Med 352(2):154–64, Epub 2005/01/14CrossRefPubMed Shahinian V, Kuo Y, Freeman J, Goodwin J (2005) Risk of fracture after androgen deprivation for prostate cancer. N Engl J Med 352(2):154–64, Epub 2005/01/14CrossRefPubMed
7.
go back to reference Smith M, Lee W, Brandman J, Wang Q, Botteman M, Pashos C (2005) Gonadotropin-releasing hormone agonists and fracture risk: a claims-based cohort study of men with nonmetastatic prostate cancer. J Clin Oncol 23(31):7897–903, Epub 2005/11/01CrossRefPubMed Smith M, Lee W, Brandman J, Wang Q, Botteman M, Pashos C (2005) Gonadotropin-releasing hormone agonists and fracture risk: a claims-based cohort study of men with nonmetastatic prostate cancer. J Clin Oncol 23(31):7897–903, Epub 2005/11/01CrossRefPubMed
8.
go back to reference Wadhwa VK, Weston R, Mistry R, Parr N (2009) Long-term changes in bone mineral density and predicted fracture risk in patients receiving androgen-deprivation therapy for prostate cancer, with stratification of treatment based on presenting values. BJU Int 104(6):800–5, Epub 11 MAR 2009CrossRefPubMed Wadhwa VK, Weston R, Mistry R, Parr N (2009) Long-term changes in bone mineral density and predicted fracture risk in patients receiving androgen-deprivation therapy for prostate cancer, with stratification of treatment based on presenting values. BJU Int 104(6):800–5, Epub 11 MAR 2009CrossRefPubMed
9.
go back to reference D’Alesio V, Salvig BE, Fourakre TN (2011) Evaluation of osteoporosis risk assessment in veterans receiving androgen-deprivation therapy. Consult Pharm : J Am Soc Consult Pharm 26(1):43–7, Epub 2011/01/13CrossRef D’Alesio V, Salvig BE, Fourakre TN (2011) Evaluation of osteoporosis risk assessment in veterans receiving androgen-deprivation therapy. Consult Pharm : J Am Soc Consult Pharm 26(1):43–7, Epub 2011/01/13CrossRef
10.
go back to reference Shao Y, Moore D, Shih W, Lin Y, Jang T, Lu-Yao G. Fracture after androgen deprivation therapy among men with a high baseline risk of skeletal complications. BJU International. 2013. Epub ahead of print Shao Y, Moore D, Shih W, Lin Y, Jang T, Lu-Yao G. Fracture after androgen deprivation therapy among men with a high baseline risk of skeletal complications. BJU International. 2013. Epub ahead of print
11.
go back to reference Alibhai SM, Duong-Hua M, Cheung AM, Sutradhar R, Warde P, Fleshner NE et al (2010) Fracture types and risk factors in men with prostate cancer on androgen deprivation therapy: a matched cohort study of 19,079 men. J Urol 184(3):918–23, Epub 2010/07/21CrossRefPubMed Alibhai SM, Duong-Hua M, Cheung AM, Sutradhar R, Warde P, Fleshner NE et al (2010) Fracture types and risk factors in men with prostate cancer on androgen deprivation therapy: a matched cohort study of 19,079 men. J Urol 184(3):918–23, Epub 2010/07/21CrossRefPubMed
12.
go back to reference Hussain S, Breunis H, Timilshina N, Alibhai SMH (2010) Falls in men on androgen deprivation therapy for prostate cancer. J Geriatr Oncol 1(1):32–9CrossRef Hussain S, Breunis H, Timilshina N, Alibhai SMH (2010) Falls in men on androgen deprivation therapy for prostate cancer. J Geriatr Oncol 1(1):32–9CrossRef
13.
go back to reference Hamdy RC, Baim S, Broy SB, Lewiecki EM, Morgan SL, Tanner SB et al (2010) Algorithm for the management of osteoporosis. South Med J 103(10):1009–15, quiz 16. Epub 2010/09/08CrossRefPubMed Hamdy RC, Baim S, Broy SB, Lewiecki EM, Morgan SL, Tanner SB et al (2010) Algorithm for the management of osteoporosis. South Med J 103(10):1009–15, quiz 16. Epub 2010/09/08CrossRefPubMed
14.
go back to reference Tosteson AN, Melton LJ 3rd, Dawson-Hughes B, Baim S, Favus MJ, Khosla S et al (2008) Cost-effective osteoporosis treatment thresholds: the United States perspective. Osteoporos Int : J Established Result Cooperation Between Eur Found Osteoporosis Natl Osteoporos Found USA 19(4):437–47, Epub 2008/02/23CrossRef Tosteson AN, Melton LJ 3rd, Dawson-Hughes B, Baim S, Favus MJ, Khosla S et al (2008) Cost-effective osteoporosis treatment thresholds: the United States perspective. Osteoporos Int : J Established Result Cooperation Between Eur Found Osteoporosis Natl Osteoporos Found USA 19(4):437–47, Epub 2008/02/23CrossRef
15.
go back to reference Alibhai SM, Rahman S, Warde PR, Jewett MA, Jaffer T, Cheung AM (2006) Prevention and management of osteoporosis in men receiving androgen deprivation therapy: a survey of urologists and radiation oncologists. Urology 68(1):126–31, Epub 2006/07/18CrossRefPubMed Alibhai SM, Rahman S, Warde PR, Jewett MA, Jaffer T, Cheung AM (2006) Prevention and management of osteoporosis in men receiving androgen deprivation therapy: a survey of urologists and radiation oncologists. Urology 68(1):126–31, Epub 2006/07/18CrossRefPubMed
16.
go back to reference Panju AH, Breunis H, Cheung AM, Leach M, Fleshner N, Warde P et al (2009) Management of decreased bone mineral density in men starting androgen-deprivation therapy for prostate cancer. BJU Int 103(6):753–7, Epub 2008/11/15CrossRefPubMed Panju AH, Breunis H, Cheung AM, Leach M, Fleshner N, Warde P et al (2009) Management of decreased bone mineral density in men starting androgen-deprivation therapy for prostate cancer. BJU Int 103(6):753–7, Epub 2008/11/15CrossRefPubMed
17.
go back to reference Van Tongeren L, Duncan G, Kendler D, Pai H (2009) Implementation of osteoporosis screening guidelines in prostate cancer patients on androgen ablation. J Clin Densitom 12(3):287–91, Epub 2009 Jul 9CrossRefPubMed Van Tongeren L, Duncan G, Kendler D, Pai H (2009) Implementation of osteoporosis screening guidelines in prostate cancer patients on androgen ablation. J Clin Densitom 12(3):287–91, Epub 2009 Jul 9CrossRefPubMed
18.
go back to reference Nadler M, Alibhai S, Catton P, Catton C, To MJ, Jones JM (2013) Osteoporosis knowledge, health beliefs, and healthy bone behaviours in patients on androgen-deprivation therapy (ADT) for prostate cancer. BJU Int 111(8):1301–9, Epub 2013/01/29CrossRefPubMed Nadler M, Alibhai S, Catton P, Catton C, To MJ, Jones JM (2013) Osteoporosis knowledge, health beliefs, and healthy bone behaviours in patients on androgen-deprivation therapy (ADT) for prostate cancer. BJU Int 111(8):1301–9, Epub 2013/01/29CrossRefPubMed
19.
go back to reference Gralow JR, Biermann JS, Farooki A, Fornier MN, Gagel RF, Kumar RN et al (2009) NCCN task force report: bone health in cancer care. J Natl Compr Cancer Netw : JNCCN 7(Suppl 3):S1–32, quiz S3-5. Epub 2009/08/15PubMedCentralPubMed Gralow JR, Biermann JS, Farooki A, Fornier MN, Gagel RF, Kumar RN et al (2009) NCCN task force report: bone health in cancer care. J Natl Compr Cancer Netw : JNCCN 7(Suppl 3):S1–32, quiz S3-5. Epub 2009/08/15PubMedCentralPubMed
20.
go back to reference Duncan G, Corbett T, Lukka H, Warde P, Pickles T (2006) GU radiation oncologists consensus on bone loss from androgen deprivation. Can J Urol 13(1):2962–6, Epub 2006/03/07PubMed Duncan G, Corbett T, Lukka H, Warde P, Pickles T (2006) GU radiation oncologists consensus on bone loss from androgen deprivation. Can J Urol 13(1):2962–6, Epub 2006/03/07PubMed
22.
go back to reference Diamond TH, Higano CS, Smith MR, Guise TA, Singer FR (2004) Osteoporosis in men with prostate carcinoma receiving androgen-deprivation therapy: recommendations for diagnosis and therapies. Cancer 100(5):892–9, Epub 2004/02/26CrossRefPubMed Diamond TH, Higano CS, Smith MR, Guise TA, Singer FR (2004) Osteoporosis in men with prostate carcinoma receiving androgen-deprivation therapy: recommendations for diagnosis and therapies. Cancer 100(5):892–9, Epub 2004/02/26CrossRefPubMed
23.
go back to reference Papaioannou A, Morin S, Cheung A, Atkinson S, Brown J, Feldman S et al (2010) Clinical practice guidelines for the diagnosis and management of osteoporosis in Canada: summary. CMAJ : Can Med Assoc J = J de l’Assoc Med Can 182(17):1864–73, Epub 2010/10/14CrossRef Papaioannou A, Morin S, Cheung A, Atkinson S, Brown J, Feldman S et al (2010) Clinical practice guidelines for the diagnosis and management of osteoporosis in Canada: summary. CMAJ : Can Med Assoc J = J de l’Assoc Med Can 182(17):1864–73, Epub 2010/10/14CrossRef
24.
go back to reference Alibhai S, Yun L, Cheung A, Paszat L (2012) Screening for osteoporosis in men receiving androgen deprivation therapy. JAMA 307(3):255–6CrossRefPubMed Alibhai S, Yun L, Cheung A, Paszat L (2012) Screening for osteoporosis in men receiving androgen deprivation therapy. JAMA 307(3):255–6CrossRefPubMed
25.
go back to reference Al-Shamsi HO, Lau AN, Malik K, Alamri A, Ioannidis G, Corbett T et al (2012) The current practice of screening, prevention, and treatment of androgen-deprivation-therapy induced osteoporosis in patients with prostate cancer. J Oncol 2012:958596, Epub 2012/05/24CrossRefPubMedCentralPubMed Al-Shamsi HO, Lau AN, Malik K, Alamri A, Ioannidis G, Corbett T et al (2012) The current practice of screening, prevention, and treatment of androgen-deprivation-therapy induced osteoporosis in patients with prostate cancer. J Oncol 2012:958596, Epub 2012/05/24CrossRefPubMedCentralPubMed
26.
go back to reference Dillman DA (1999) Mail and internet surveys—the tailored design method. Wiley, New York Dillman DA (1999) Mail and internet surveys—the tailored design method. Wiley, New York
27.
go back to reference (WHO) WHO (1994) Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. Report of a WHO Study Group. World Health Organ Tech Rep Ser 843:1–129, Epub 1994/01/01 (WHO) WHO (1994) Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. Report of a WHO Study Group. World Health Organ Tech Rep Ser 843:1–129, Epub 1994/01/01
28.
go back to reference Bolland MJ, Avenell A, Baron JA, Grey A, MacLennan GS, Gamble GD et al (2010) Effect of calcium supplements on risk of myocardial infarction and cardiovascular events: meta-analysis. BMJ 341:c3691, Epub 2010/07/31CrossRefPubMedCentralPubMed Bolland MJ, Avenell A, Baron JA, Grey A, MacLennan GS, Gamble GD et al (2010) Effect of calcium supplements on risk of myocardial infarction and cardiovascular events: meta-analysis. BMJ 341:c3691, Epub 2010/07/31CrossRefPubMedCentralPubMed
29.
go back to reference Wilcox A, Carnes M, Moon T, Tobias R, Baade H, Stamos E et al (2006) Androgen deprivation in veterans with prostate cancer: implications for skeletal health. Ann Pharmacother 40(12):2107–14, Epub 2006 Nov 28CrossRefPubMed Wilcox A, Carnes M, Moon T, Tobias R, Baade H, Stamos E et al (2006) Androgen deprivation in veterans with prostate cancer: implications for skeletal health. Ann Pharmacother 40(12):2107–14, Epub 2006 Nov 28CrossRefPubMed
30.
go back to reference Walker LM, Tran S, Wassersug RJ, Thomas B, Robinson JW. Patients and partners lack knowledge of androgen deprivation therapy side effects. Urologic oncology. 2012. Epub 2012/01/31 Walker LM, Tran S, Wassersug RJ, Thomas B, Robinson JW. Patients and partners lack knowledge of androgen deprivation therapy side effects. Urologic oncology. 2012. Epub 2012/01/31
31.
go back to reference Watson PW, McKinstry B (2009) A systematic review of interventions to improve recall of medical advice in healthcare consultations. J R Soc Med 102(6):235–43, Epub 2009/06/18CrossRefPubMedCentralPubMed Watson PW, McKinstry B (2009) A systematic review of interventions to improve recall of medical advice in healthcare consultations. J R Soc Med 102(6):235–43, Epub 2009/06/18CrossRefPubMedCentralPubMed
32.
go back to reference Kastner M, Straus S (2008) Clinical decision support tools for osteoporosis disease management: a systematic review of randomized controlled trials. J Gen Intern Med 23(12):2095–105, Epub 2008 Oct 4CrossRefPubMedCentralPubMed Kastner M, Straus S (2008) Clinical decision support tools for osteoporosis disease management: a systematic review of randomized controlled trials. J Gen Intern Med 23(12):2095–105, Epub 2008 Oct 4CrossRefPubMedCentralPubMed
33.
go back to reference Nadler M, Alibhai S, Catton P, Catton C, Jones J. The impact of bone mineral density testing, fracture assessment, and osteoporosis education in men treated by androgen deprivation for prostate cancer: a pilot study. Support Care Cancer. 2014. Epub 2014/04/04 Nadler M, Alibhai S, Catton P, Catton C, Jones J. The impact of bone mineral density testing, fracture assessment, and osteoporosis education in men treated by androgen deprivation for prostate cancer: a pilot study. Support Care Cancer. 2014. Epub 2014/04/04
34.
go back to reference Tanvetyanon T (2005) Physician practices of bone density testing and drug prescribing to prevent or treat osteoporosis during androgen deprivation therapy. Cancer 103(2):237–41, Epub 2004/12/15CrossRefPubMed Tanvetyanon T (2005) Physician practices of bone density testing and drug prescribing to prevent or treat osteoporosis during androgen deprivation therapy. Cancer 103(2):237–41, Epub 2004/12/15CrossRefPubMed
35.
go back to reference Yee E, White R, Murata G, Handanos C, Hoffman R (2007) Osteoporosis management in prostate cancer patients treated with androgen deprivation therapy. J Gen Intern Med 22:1305–10CrossRefPubMedCentralPubMed Yee E, White R, Murata G, Handanos C, Hoffman R (2007) Osteoporosis management in prostate cancer patients treated with androgen deprivation therapy. J Gen Intern Med 22:1305–10CrossRefPubMedCentralPubMed
36.
go back to reference Morgans AK, Smith MR, O’Malley AJ, Keating NL (2013) Bone density testing among prostate cancer survivors treated with androgen deprivation therapy. Cancer 119(4):863–70, Epub 2012/10/16CrossRefPubMedCentralPubMed Morgans AK, Smith MR, O’Malley AJ, Keating NL (2013) Bone density testing among prostate cancer survivors treated with androgen deprivation therapy. Cancer 119(4):863–70, Epub 2012/10/16CrossRefPubMedCentralPubMed
37.
go back to reference Suarez-Almazor ME, Peddi P, Luo R, Nguyen HT, Elting LS (2014) Low rates of bone mineral density measurement in Medicare beneficiaries with prostate cancer initiating androgen deprivation therapy. Support Care Cancer 22(2):537–44, Epub 2013/10/23CrossRefPubMed Suarez-Almazor ME, Peddi P, Luo R, Nguyen HT, Elting LS (2014) Low rates of bone mineral density measurement in Medicare beneficiaries with prostate cancer initiating androgen deprivation therapy. Support Care Cancer 22(2):537–44, Epub 2013/10/23CrossRefPubMed
38.
go back to reference Ito K, Elkin EB, Girotra M, Morris MJ (2010) Cost-effectiveness of fracture prevention in men who receive androgen deprivation therapy for localized prostate cancer. Ann Intern Med 152(10):621–9, Epub 2010/05/19CrossRefPubMed Ito K, Elkin EB, Girotra M, Morris MJ (2010) Cost-effectiveness of fracture prevention in men who receive androgen deprivation therapy for localized prostate cancer. Ann Intern Med 152(10):621–9, Epub 2010/05/19CrossRefPubMed
39.
go back to reference DeJesus RS, Angstman KB, Kesman R, Stroebel RJ, Bernard ME, Scheitel SM et al (2012) Use of a clinical decision support system to increase osteoporosis screening. J Eval Clin Pract 18(1):89–92, Epub 2010/08/21CrossRefPubMedCentralPubMed DeJesus RS, Angstman KB, Kesman R, Stroebel RJ, Bernard ME, Scheitel SM et al (2012) Use of a clinical decision support system to increase osteoporosis screening. J Eval Clin Pract 18(1):89–92, Epub 2010/08/21CrossRefPubMedCentralPubMed
40.
go back to reference Feldstein A, Elmer PJ, Smith DH, Herson M, Orwoll E, Chen C et al (2006) Electronic medical record reminder improves osteoporosis management after a fracture: a randomized, controlled trial. J Am Geriatr Soc 54(3):450–7, Epub 2006/03/23CrossRefPubMed Feldstein A, Elmer PJ, Smith DH, Herson M, Orwoll E, Chen C et al (2006) Electronic medical record reminder improves osteoporosis management after a fracture: a randomized, controlled trial. J Am Geriatr Soc 54(3):450–7, Epub 2006/03/23CrossRefPubMed
41.
go back to reference Francke AL, Smit MC, de Veer AJ, Mistiaen P (2008) Factors influencing the implementation of clinical guidelines for health care professionals: a systematic meta-review. BMC Med Inform Decis Mak 8:38, Epub 2008/09/16CrossRefPubMedCentralPubMed Francke AL, Smit MC, de Veer AJ, Mistiaen P (2008) Factors influencing the implementation of clinical guidelines for health care professionals: a systematic meta-review. BMC Med Inform Decis Mak 8:38, Epub 2008/09/16CrossRefPubMedCentralPubMed
43.
go back to reference Shahinian VB, Kuo YF (2013) Patterns of bone mineral density testing in men receiving androgen deprivation for prostate cancer. J Gen Intern Med 28(11):1440–6, Epub 2013/05/15CrossRefPubMedCentralPubMed Shahinian VB, Kuo YF (2013) Patterns of bone mineral density testing in men receiving androgen deprivation for prostate cancer. J Gen Intern Med 28(11):1440–6, Epub 2013/05/15CrossRefPubMedCentralPubMed
Metadata
Title
Bone health management in men undergoing ADT: examining enablers and barriers to care
Authors
A. N. Damji
K. Bies
S. M. H. Alibhai
J. M. Jones
Publication date
01-03-2015
Publisher
Springer London
Published in
Osteoporosis International / Issue 3/2015
Print ISSN: 0937-941X
Electronic ISSN: 1433-2965
DOI
https://doi.org/10.1007/s00198-014-2997-6

Other articles of this Issue 3/2015

Osteoporosis International 3/2015 Go to the issue